Connecting European Neuroscience
FENS offers a range of state of the art platforms for interacting international researchers from the entire spectrum of neuroscience disciplines.
Visit the FENS meetings portal to get more information.
In collaboration with prominent and long-standing partners of FENS, new programmes for European higher education – schools and training – will be offered every year.
Visit the FENS Training portal to get more information.
Check out the latest articles and news of EJN. All FENS members have FREE access to EJN!
Visit the FENS website to get more information.
FENS calls on the European Parliament and Commission to reaffirm their commitment to the Directive.
Visit the FENS Outreach portal to get more information.
FENS provides its members with a full package of services to facilitate the exchange of information and enhance networking activities among neuroscientists.
Visit the FENS Societies portal to get more information.
01 August, 2006
in Neuroscience News
Brain disease psychiatric and neurologic disease combined represents a considerable social and economic burden in Europe. Data collected by the World Health Organization (WHO) suggest that brain diseases are responsible for 35% of Europe’s total disease burden. An analysis of all health economic studies of brain diseases in Europe, published by the European Brain Council (EBC) in June 2005, estimated the total cost of brain disease in Europe in 2004 to be €386 billion. That burden is set to grow, mainly due to the fact that the European population is ageing.
Investment in brain sciences does not match that burden now, let alone in the future. Brain research received only 8% of the life science budget in the European Commission’s Fifth Framework Programme, which represents less than 0.01% of the annual cost of brain disorders for that period. Over the last decade, Europe has been losing ground to the USA and Japan in terms of both basic and clinical research. Many of Europe’s young researchers are taking up posts in the USA and staying there. Big pharmaceutical companies are fleeing Europe for the USA, taking their drug development programmes with them.
Research in the brain sciences now holds the promise of therapies that halt and even reverse neurodegeneration, of better diagnostic tools, neural prostheses for the paralysed and drugs for depression and anxiety that are tailored to the individual, thereby eliminating or reducing side effects. Our growing understanding of the normal brain could lead to better prevention of brain disease and to more effective teaching methods. The need for innovative treatments has never been greater, and Europe boasts clusters of excellent researchers in biotechnology who could collaborate with brain scientists and the pharmaceutical industry to realise this promise.
Become a FENS Member by registering with one of the FENS member Societies.FENS member societies are independent scientific organizations with individual guidelines and rules for membership. You are encouraged to check the particular guidelines for membership before submitting your expression of interest to become a FENS member. You can find an overview of all FENS societies here: www.fens.org/societies.Please enter your contact details below, and the indicated FENS member Society will approach you with further membership information.
By submitting this form, you provide your consent to the use and storage of your personal data for purposes related to your membership.*
Please insert your email address in the form below and we will contact you.